|  | 

News and Headlines

Higher rate of heart problems with Amgen osteoporosis drug in trial

img-responsive

Higher rate of heart problems with Amgen osteoporosis drug in trial(Reuters) – Amgen Inc and UCB SA on Sunday said they do not expect their experimental osteoporosis drug to win U.S. approval this year after a higher rate of serious heart-related side effects were observed in a late stage clinical trial. The drug, romosozumab, which would be sold under the brand name Evenity if approved, is awaiting an approval decision by the Food and Drug Administration. At the same time, the newly observed cardiovascular safety signal will have to be assessed as part of the overall benefit/risk profile for Evenity,” Amgen research chief Sean Harper said in a statement.


higher-rate-of-heart-problems-with-amgen-osteoporosis-drug-in-trial

ABOUT THE AUTHOR

POST YOUR COMMENTS

Your email address will not be published. Required fields are marked *

Name *

Email *

Website